Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Conditions: Newly Diagnosed Multiple Myeloma
Interventions: Biological: AZD0120; Biological: Daratumumab; Drug: Dexamethasone; Biological: Isatuximab; Drug: Lenalidomide; Drug: Bortezomib; Drug: Cyclophosphamide; Drug: Fludarabine
Sponsors: AstraZeneca
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 15, 2026Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine
Comments